IMPORTANCE A national policy is under consideration to reduce the nicotine content of cigarettes to lower nicotine addiction potential in the United States.
C igarette smoking is a public health burden that especially harms individuals with psychiatric conditions and socioeconomic disadvantage and is a major contributor to health disparities. [1] [2] [3] [4] [5] Reducing this burden will require tobacco control and regulatory policies that are more effective at changing behavior in these vulnerable populations. 6 The present study investigates how vulnerable populations of smokers may respond to a national US regulatory policy to reduce the maximal nicotine content of cigarettes and thereby lower their potential to cause addiction. The 2009 Family Smoking Prevention and Tobacco Control Act (FSPTCA) granted the US Food and Drug Administration regulatory authority over cigarettes and other tobacco products. 7 That legislation includes authority to reduce the maximal nicotine content of cigarettes if doing so benefits public health. A regulatory question fundamental to protecting public health is whether the nicotine content of cigarettes can be set below a threshold dose necessary to produce or sustain addiction. This would allow current smokers to make more rational choices about continuing to smoke while lowering addiction risk among those newly introduced to smoking. Benowitz and Henningfield 8 introduced the idea of decreasing nicotine content more than 20 years ago, hypothesizing that the threshold nicotine dose for reinforcing effects, a primary indicator of addiction potential, was approximately 0.7 mg/g of tobacco. A series of studies [9] [10] [11] [12] in relatively healthy smokers conducted since the passage of the FSPTCA support the position that reducing nicotine content in cigarettes to very low levels reduces addiction potential. Moreover, cigarettes with reduced nicotine content appear to produce minimal compensatory smoking (ie, adjustments in smoking amount or topography to sustain desired nicotine blood levels). [9] [10] [11] [12] Compensatory smoking was the major limitation in prior efforts to use light cigarettes to reduce addiction potential 13 that attempted to reduce nicotine yield through filter ventilation but left the nicotine content unchanged. Initial studies of cigarettes with reduced nicotine content were appropriately conducted with psychiatrically and socioeconomically stable, healthy smokers. However, smoking is overrepresented among those with psychiatric conditions and socioeconomic disadvantage, among other vulnerabilities. [1] [2] [3] [4] [5] [6] 14, 15 Thus, we studied 3 adult populations that are particularly vulnerable to tobacco addiction and its adverse health impacts: individuals with affective disorders to represent smokers with mental illness, individuals with opioid dependence to represent smokers with other substance use disorders, and socioeconomically disadvantaged women to represent smokers with socioeconomic disadvantage. [1] [2] [3] [4] [5] [6] [14] [15] [16] Disadvantaged women of reproductive age are of special interest because of their risk for smoking during pregnancy and while parenting young children. 14 Smoking prevalence in each of these populations exceeds prevalence in the US adult population (21.0%; 95% CI, 20.4%-21.6%), with rates of 32.2% (95% CI, 30.3%-34.1%) among those with affective disorders, 92.2% (95% CI, 86.5%-97.9%) among those with opioid (heroin) dependence, and 29.5% (95% CI, 28.0%-31.0%) among disadvantaged women of reproductive age. 17 How smokers with comorbid psychiatric conditions or lower socioeconomic status respond to cigarettes with reduced nicotine content has not been well studied. Several small studies involving these vulnerable populations suggest that cigarettes with very low nicotine content reduce abstinenceinduced withdrawal without engendering compensatory smoking. [18] [19] [20] [21] Results from a single pilot study 21 suggest that reducing the nicotine content decreases the addiction potential of smoking among individuals with psychiatric conditions or socioeconomic disadvantage, but a small sample size precluded thoroughly examining the nicotine dose or population differences. Another study 22 demonstrated that elevated depressive symptoms did not moderate response to reduced nicotine content cigarettes, although this was not in a clinically diagnosed sample. The current study is, to our knowledge, the first large, controlled study to examine the dosedependent effects of cigarettes with reduced nicotine content on the reinforcing effects, subjective effects, and smoking topography in vulnerable populations.
Methods

Study Sample
Participating adult daily smokers included 56 with affective disorders, 60 with opioid dependence, and 53 socioeconomically disadvantaged women ( Table 1) . Inclusion and exclusion criteria are described in eMethods in the Supplement. The institutional review boards at the University of Vermont, Burlington; Brown University, Providence, Rhode Island; and Johns Hopkins University School of Medicine, Baltimore, Maryland, approved the study. All participants provided written informed consent.
their usual-brand cigarette. In sessions 2 to 5, participants smoked 1 research cigarette per session. The research cigarettes were identical in appearance but varied in nicotine content (15.8, 5.2, 2.4, and 0.4 mg/g; Spectrum cigarettes, 22nd Century Group, Inc). The highest dose served as a control for nicotine levels typical of commercial cigarettes, whereas the lowest dose represents a dose below the hypothesized 0.7-mg/g threshold dose for addiction. Participants were instructed to smoke the research cigarettes as usual but used a plastic cigarette holder connected to a device that recorded smoking topography. 23 After smoking the assigned cigarette each session, participants completed the Cigarette Purchase Task (CPT), which is a behavioral economic simulation task that models (1) cigarette smoking rate when unconstrained by cost, (2) maximal amount of money that an individual is willing to spend on daily smoking, (3) the price at which the smoking rate begins decreasing proportionate to increasing price, (4) the price at which an individual would quit smoking rather than incur the cost, and (5) overall sensitivity of smoking rate to price. [24] [25] [26] In addition, the modified Cigarette Evaluation Ques- Phase 2 (sessions 6-11) directly tested the relative reinforcing effects of the different doses in the cigarettes by allowing participants to choose which cigarette they preferred to smoke.
31,32 Each of the 6 possible cigarette dose-pair combinations was tested once in separate sessions. In these 3-hour sessions, a participant sat alone in a comfortable, ventilated room with reading materials (eFigure 1 in the Supplement). When they wished to smoke, they used a computer mouse to click on 1 of 2 icons on a screen representing the 2 cigarettes available that session. After 10 clicks on the icon, they could take 2 puffs of the associated cigarette. 31 Participants were free to choose either option as often as they wished or to abstain. Last, phase 3 (sessions [12] [13] [14] used the same arrangement as in phase 2 but compared only the lowest and highest doses (0.4 and 15.8 mg/g). This phase assessed whether preference could be reliably shifted away from the high dose. Puffs from the low dose were always available by clicking that option 10 times, but the number of clicks necessary to earn puffs from the highest dose started at 10 and increased each time it was chosen to 160, 320, 640, 1280, 2400, 3600, 4800, 6000, 7200, and 8400 clicks.
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Participants were informed of the different response requirements in advance. Participants completed the CPT for the 0.4-and 15.8-mg/g doses after the concurrent choice sessions in phase 3 to assess relative demand for the 2 cigarettes outside the concurrent choice test arrangement.
Statistical Methods
Analyses of phase 1 results examined differences between the research cigarettes on the CPT and mCEQ and smoking topography by using repeated-measures analysis of variance, with nicotine dose as the within-participant factor. The MNWS, QSUBrief, and breath levels of carbon monoxide (CO) boost were examined similarly with time as another within-participant factor. To measure CO boost, presmoking CO values were subtracted from postsmoking CO values. Analyses also included a fixed effect for session. Time-by-dose interactions were included to test whether the CO boost or subjective effects before and after smoking differed by dose; when not significant, interaction effects were dropped from the models. Because the research cigarettes were presented in random order using a Latin square, sequence was included in the model as a random effect. An additional random effect was included to account for the 3 study sites and a fixed effect to examine population differences. Significant time, dose, or interaction effects were followed by post hoc testing using Bonferroni corrections. Differences in preference among all possible dose pairs (phase 2) were similarly examined using repeated-measures analysis of variance, with each pairwise combination as the withinparticipant factor. Significant dose-pair effects were followed with post hoc testing. Differences among participants in preference for the highest-vs lowest-dose cigarettes (phase 3) were examined using a repeated-measures analysis of variance, with session as the repeating factor and population as the betweensubjects factor. Effect sizes were computed using the Cohen d for pairwise comparisons and η 2 value for interaction effects. Exploratory analyses examining possible moderating effects of sex and cigarette mentholation status were conducted with 2 primary outcome measures (concurrent choice and mCEQ). To describe aggregate-level cigarette demand on the CPT, we fit a demand curve 34 to mean reported consumption at each price across participants and doses. An extra sum-of-squares F test evaluated whether demand inelasticity differed significantly across doses; this test was also used to compare aggregate dose curves across populations and sessions.
To quantify participant-level CPT demand elasticity, a demand curve was fit to individual consumption at each price for each dose. When fitting demand curves, we constrained demand intensity to the participants' reported consumption at $0.00 to leave elasticity as the only fitted parameter. Elasticity values greater than 1.00 were winsorized to 1.00 before statistical analysis (22 of 845 cases). All other demand indices were empirically quantified from observed values. Maximal expenditure, maximal price, breakpoint, and α values were log 10 transformed to correct for skewness. We reviewed CPT results and found systematic patterns 35 in 92.7% of demand curves; no data were excluded from analyses. In cases in which participants reported zero consumption across all prices, curve fitting was not possible; thus, elasticity was not analyzed and other demand indices were quantified as 0. Data were complete for all but the MNWS, QSU-Brief, and smoking topography measures. Missing data for topography measures amounted to 3% or less, whereas missing data for the other measures was limited to at most 2 missing observations per session. All analyses were completed using maximum likelihood estimation procedures. Significance for all tests was P < .05. Post hoc testing was based on unpaired t tests (between participants) or paired t tests (within participant). All were 2-tailed, with P values for post hoc tests subject to Bonferroni correction.
Results
Direct Testing
One hundred sixty-nine daily smokers (120 [11.4] years) were included in the analyses. In concurrent choice testing with the cigarettes available at an equal response effort, participants chose those with higher compared with lower nicotine content across each of the 6 dose pairs, a finding consistent with cigarettes with reduced nicotine content having lower addiction potential (t 159 >2.96; P < .008) ( Figure 1A ). The only difference between populations (F 2,154 =3.27;P = .04) in that regard was at the 0.4-vs 2.4-mg/g dose pair, at which smokers with affective disorders chose the higher dose more frequently (t 154 = 3.46; P < .001), whereas disadvantaged women (t 154 = 1.92; P = .06) and participants with opioid dependence (t 154 = 0.11; P = .91) did not exhibit a significant preference between those 2 doses (eFigure 2 in the Supplement).
When concurrent choice testing in phase 3 involved a greater effort to obtain the cigarette with the highest vs lowest nicotine content cigarette (15.8 vs 0.4 mg/g), preference was reversed from that when those same doses were available at equal response effort ( Figure 1B ). Participants more frequently chose to smoke the cigarette with the 0.4-mg/g dose than the cigarette with the 15.8-mg/g dose (t 160 = 4.73; P < .001), with no differences across sessions (F 2,293 = 0.03; P = .78) or populations (F 2,160 = 0.41; P = .67). We found no significant interactions of dose and sex or cigarette mentholation status with choice between dose pairs (F 5,831 ≤1.86; P ≥ .05).
Simulation
Mean estimated rate of cigarette smoking in the CPT decreased as a function of increasing price across the 4 doses in a manner described by an exponential demand equation (Figure 2A) . The estimated rate of smoking decreased as a function of decreasing nicotine dose (F 3,75 = 5.40; P = .002). No population differences were found except at the 2.4-mg/g dose (F 2,57 = 14.00; P < .001), at which smoking rate was greater among those with opioid dependence than among smokers with affective disorders (F 1,38 = 20.00; P < .001) and disadvantaged women (F 1,38 = 21.00; P < .001) (eFigure 3A in the Supplement). Significant effects of nicotine dose were also observed across 4 of the 5 CPT indices, including the number of cigarettes that participants estimated smoking per day if cigarettes were free of cost (demand intensity) ( Figure 2B ), how much they were willing to spend daily on smoking (maximum expenditure) ( Figure 2C ), price at which the smoking rate began to decrease proportionate to increasing price (maximum price) ( Figure 2D ), and of particular relevance to addiction potential, the price at which participants indicated they would quit smoking rather than incur the cost (breakpoint) ( Figure 2E ) (F 3,484 ≥5.38; P ≤ .001). Overall sensitivity to price did not increase significantly as nicotine dose decreased (F 3,437 = 2.62; P = .05) ( Figure 2F ). The only effect of population (F 2,97 = 5.02; P = .008) across these 5 indices was with cigarettes smoked per day if free of cost (demand intensity) (eFigure3BintheSupplement), with greater smoking among those with opioid dependence compared with disadvantaged women (t 163 = 3.02; P = .009). We found no significant interactions between nicotine dose and population (F 6,484 ≤0.98; P > .05). A small proportion of participants reported zero demand across all prices that varied by dose for 0. The CPT assessments were also completed at the end of phase 3 sessions. Demand remained higher for the 15.8-vs 0.4-mg/g dose (F 1,38 = 7.45; P = .01) (eFigure 4 in the Supplement), suggesting that the preference reversal observed in the concurrent choice tests resulted from the greater effort required to obtain the high dose and not a generalized change in the relative reinforcing value of the 2 doses. We found no significant differences across sessions or populations.
Participant Ratings and Compensatory Smoking Measures
In tests of subjective effects, positive ratings of smoking on the mCEQ decreased as a function of reducing nicotine content, a finding consistent with reduced addiction potential (F 3,501 ≥7.08; P < .001) ( Table 2) ; there were no significant interactions between dose and sex or cigarette mentholation status (F 3,495 ≤2.33; Ps ≥.05). Each of the doses significantly reduced nicotine withdrawal symptoms and craving on the MNWS (t 2016 >2.67; P < .001), although duration of effects was greater at higher doses ( Table 3 ) (dose-by-time interaction; F 12,2014 =2. 64;P = .002). Results of the QSU-Brief are found in eTable 1 in the Supplement. Only 1 significant difference between populations was found for the MNWS total score (main effect; F 2,166 = 7.54; P = .001), with symptoms among disadvantaged women significantly lower than among individuals with opioid dependence (t 166 = −2.42; P = .02) or affective disorders (t 95 = −3.81; P < .001).
No significant changes were noted across doses in smoking topography (eFigure 5 in the Supplement)orbreathCOexposure levels (eTable 2 in the Supplement) indicative of compensatory smoking. The results suggest that participants may smoke the reduced nicotine content cigarettes less intensely. These effects were consistent across populations.
Discussion
Overall, our results indicate that reducing the nicotine content of cigarettes reduces the relative reinforcing effects of smoking and thus addiction potential in populations with psychiatric conditions and other vulnerabilities to tobacco as the 0.4-mg/g dose (phase 2; left) and when it was available at different response effort (progressive ratio starting at 10 responses that incremented upward to a maximum of 8400 responses) compared with the 4-mg/g dose (fixed-ratio 10) (phase 3; right). Phase 2 and phase 3 are described in the Procedure subsection of the Methods section. Data points represent means across participants and sessions (phase 3); error bars, SEM.
a Statistically significant difference at P < .05 after Bonferroni correction.
addiction. Although this association was graded with no clear threshold effect, the 0.4-mg/g dose most consistently and robustly differed from the 15.8-mg/g control dose, a finding supporting a prior hypothesis about reducing nicotine content below 0.7 mg/g. 8 A thresholdlike effect was reported previously in a trial examining chronic exposure among more medically and socially stable smokers who maintained lower rates of smoking at doses of 2.4 mg/g or less compared with higher doses. 12 Whether a similar pattern emerges during extended exposure in more vulnerable populations should be examined in future studies.
Reductions in reinforcing effects were achieved in the present study without causing untoward withdrawal, craving, or compensatory smoking. The consistency of effects noted across the 3 vulnerable populations underscores the generality of these results, especially regarding the control that nicotine content exerts over smoker preferences, despite considerable individual differences. Overall, the present findings are consistent with the lower smoking rates, decreased nicotine dependence severity, increased quit attempts, and lower intensity of demand observed in clinical trials of cigarettes with reduced nicotine content among more stable smokers. ; maximal expenditure, estimated maximal expenditure participants were willing to incur for smoking in 1 day (range, 0-1600, with higher scores indicating greater expenditure); maximal price, estimated price at which demand begins to decrease proportional to price increases (range, 0-40, with higher scores indicating a greater cigarette unit price associated with unit elasticity for cigarettes); breakpoint, estimated price at which participants would quit smoking rather than incur its costs (range, 0-60, with higher scores indicating a greater cigarette unit price associated with discontinuation of smoking); and α, estimated overall sensitivity of demand to price increases (range, 1.096 −20 to 1, with higher scores indicating greater sensitivity to cigarette unit price increases). Data points not sharing a symbol differ significantly (P < .05) after Bonferroni correction. The ability of increased response cost to shift preference to the 0.4-vs 15.8-mg/g dose ( Figure 1B ) suggests that cigarettes with very low nicotine content can serve as economic substitutes for cigarettes with commercial-level nicotine content when the cost to obtain the higher-dose products is greater. This observation is consistent with unit-price models of drug abuse wherein reinforcing value corresponds to the ratio of drug dose and cost. 37, 38 This observation has considerable tobacco regulatory implications. For example, allowing cigarettes with very low nicotine content to be sold in common retail outlets while restricting the sale of cigarettes with higher nicotine content to less plentiful or more regulated stores would be predicted to shift preference toward the former. This same concept may also extend to regulatory efforts to shift preference from combusted to less harmful noncombusted tobacco products.
Over time, smokers with comorbid psychiatric conditions and socioeconomic disadvantage have become a larger proportion of smokers in developed countries, in part because they are more addicted and thus less likely to try to quit or to succeed if they try. [1] [2] [3] [4] [5] [6] 14, 15 Smoking in these populations is an important contributor to health disparities. 2, 3 Thus, it is important that tobacco control and regulatory policies are developed that are effective among populations with comorbid psychiatric conditions and socioeconomic disadvantage.
Limitations
The present study assessed acute response in a laboratory setting, leaving unanswered whether results can be generalized to vulnerable populations with chronic use of cigarettes with reduced nicotine content in naturalistic settings. That question can only be answered by field trials in vulnerable populations, which are under way. The acute laboratory model was an appropriately safe setting to begin examining cigarettes with reduced nicotine content in medically and socially unstable populations. The laboratory models used in the present study are well-validated methods for assessing the addiction potential of drugs in naturalistic settings.
39,40
Results from prior studies of acute response to cigarettes with reduced nicotine content in laboratory settings in the general population of smokers used similar methods, 32, 41 and results align closely with those seen during chronic exposure in naturalistic settings. 12 
Conclusions
Our results suggest that a national regulatory policy reducing the nicotine content of cigarettes may reduce the addiction potential of cigarettes and that those effects would extend to populations that are highly vulnerable to tobacco addiction. In addition, the results suggest how regulatory policies could potentially shift preferences from moreto less-harmful tobacco products. Studies of extended exposure to reduced nicotine content cigarettes and studies in populations with other psychiatric conditions are warranted. an application for an Investigational Tobacco Product with the Center for Tobacco Products, U.S. FDA. These products have been described previously. 1 Four nicotine dose conditions were investigated using research cigarettes defined according to the nicotine content, averaged across menthol and non-menthol products (assignment of a menthol or non-menthol product was based on a participant's reported usual brand): 15.8, 5.2, 2.4, and 0.4 mg of nicotine per gram of tobacco (mg/g). These cigarettes also differed in the content or yield of minor alkaloids and nitrosamines and in the application of casings, including sugars (which were higher in the 15.8 mg/g cigarettes than in the reduced-nicotine cigarettes in order to balance the ratio of nicotine to sugar). All sessions were conducted under double-blind conditions with the varying dose cigarettes being represented by letter codes. The dose and letter code combinations were determined randomly.
ARTICLE INFORMATION
Procedure
Participants completed fourteen 2-4 hour experimental sessions (> 48 hours between sessions) in a within-subjects design. Experimental sessions were conducted in ventilated observation rooms (at least 4.3×5.9× 7.3 ft) equipped with Acer Aspire ES1-111 series laptops with 11.6" monitors that were used for completing questionnaires and for indicating cigarette preference in concurrent choices sessions (described below). Rooms were also equipped with Dell Optiplex 740 series computers that ran on Windows XP Professional and with 15" CRT monitors that were used for controlling smoke exposure (described below).
Experimental sessions were conducted following brief smoking abstinence (< 50% baseline breath CO level). Participants were instructed that they should try to abstain from smoking for at least 6-8 hrs in order to meet the breath CO criterion. Sessions were rescheduled if the abstinence criterion was not met. Experimental sessions could be scheduled in mornings, afternoons, or evenings, but were conducted at approximately the same time of day across sessions within individual participants. Upon arrival at the laboratory, participants completed a brief battery of physiological measures, including breath CO, BAL, urine toxicology screen for drugs of abuse, urine pregnancy test, weight, heart rate, and blood pressure. Experimental sessions were rescheduled for those who failed to meet the < 50% baseline breath CO criterion or had a BAL > .03%. Those with a positive drug screen were administered a field sobriety test: if passed the session was conducted and if failed the session was rescheduled. A positive pregnancy test resulted in discontinuation from the study.
At the beginning of each experimental session, participants were instructed to take two puffs from their usual brand cigarette under staff observation to equate time since last cigarette across study participants. 6 Experimental sessions began 30 min following completion of the two puffs. During that 30-min wait period, participants completed the Minnesota Nicotine Withdrawal Scale (MNWS) 7 and the Questionnaire of Smoking Urges-brief scale (QSU-brief) 8 . No eating or drinking other than water was permitted during sessions.
Briefly, the 14 sessions were organized into three phases: Phase 1 (Sessions 1-5) involved simulating demand for smoking each of the research cigarettes using the Cigarette Purchase Task (CPT) 9, 10 , and assessments of subjective effects of smoking 7, 8, 11 and smoking topography 12 . Phase 2 (Sessions 6-11) involved assessment of preference between all dose-pairs of the four research cigarettes using free-operant concurrent choice procedures with each available at a relatively low response requirement (Fixed-Ratio 10). 13, 14 Phase 3 (Sessions 12-14) involved assessment of preference for lowest dose cigarette (0.4 mg/g) at the same low response requirement (Fixed-Ratio 10) vs. the 15.8 mg/g dose available on an 11-step progressive ratio schedule (10, 160, 320, 640, 1280, 2400, 3600, 4800, 6000, 7200, and 8400 where it was maintained until session completion). 15 Detailed procedures for each phase are presented in the sections that follow.
Phase 1 (Sessions 1-5)
Participants smoked usual brand cigarettes in Session 1; in Sessions 2-5, participants were exposed to the different dose research cigarettes, one dose per session with order of exposure randomized across sessions and participants. All cigarettes were smoked using a Clinical Research Support System (CReSS) Desktop smoking topography device (Borgwaldt KC, Richmond, VA). Individuals smoked each cigarette through a plastic cigarette holder that was attached to an air-filled tube, which leads to a pressure transducer. The device measures and records a number of smoking topography parameters, namely, (1) puff volume, (2) puff duration (3) maximum flow rate, and (4) total number of puffs. 12 Each cigarette was smoked ad libitum to assess potential differences in smoking topography across the varying dose cigarettes.
Following completion of smoking the assigned cigarette in each session, participants were encouraged to make detailed notes about the cigarette (identified by letter code) which were available to them for use in Phases 2 and 3 when they had the opportunity to choose between smoking the different investigational cigarettes. Next, they completed the CPT 9,10 and the modified Cigarette Evaluation Questionnaire (mCEQ) 11 . The CPT is a behavioral economic task measuring the relative reinforcing value of smoking in monetary terms (i.e., cigarette demand). Prior studies have shown that results are congruent across versions where participants consume purchased cigarettes as part of the experimental sessions and a hypothetical version where participants estimate how many cigarettes they would consume at varying prices. 16 A hypothetical purchase task was used in the present study. Participants were instructed to imagine they had the same income/savings that they had right now, no access to any cigarettes or nicotine products other than those offered at these prices, they could smoke without any restrictions for the next 24 hours and they would smoke the cigarettes they requested at this time and could not save or stockpile cigarettes for a later date. Twenty prices per cigarette were assessed: $0.00 (free), $0.02, $0.05, $0.10, $0.20, $0.30, $0.40, $0.50, $0.60, $0.70, $0.80, $0.90, $1.00, $2.00, $3.00, $4.00, $5.00, $10.00, $20.00, and $40.00. At each price, participants were informed about the corresponding price per pack of cigarettes in addition to the price per cigarette. The mCEQ is a reliable and valid five-factor instrument that assesses subjective effects associated with the reinforcing and aversive effects of cigarette smoking.
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Unlike the CPT and mCEQ, which were completed once per session, participants provided expired CO samples and completed validated measures of nicotine withdrawal and craving (MNWS 6 , QSU-brief 7 ), at 15-, 30-, 45-, and 60-min following completion of smoking.
Phase 2 (Sessions 6-11)
Upon arrival at the laboratory, participants completed the same battery of physiological measures as described above, took two puffs from their usual brand cigarette and completed the MNWS 6 and QSU-brief 7 questionnaires during the 30-min wait period between puffs and start of the experimental session. Upon initiation of the 3-hour experimental session, two different packs of research cigarettes were made available to participants, each with a different letter code (see eFigure 1). These letter codes corresponded to the same letter codes used with individual participants in the exposure sessions in Phase 1. Participants were encouraged to consult any notes they had made about each of the research cigarettes during the exposure sessions. Each of the possible 6 dose pairs was evaluated once per participant in random order and under double-blind conditions. Participants were instructed that they were free to choose to smoke either of the research cigarettes as often as they preferred and that they were also free to forego smoking either of the available cigarettes if that was their preference. 11 The computer screen displayed two 1.25 inch squares with each having one of the two letter codes of the cigarettes available for that session embedded within each square. When participants wished to smoke, they used the computer mouse to direct the cursor to the desired square and associated letter code and clicked the mouse ten times (Fixed-Ratio 10). After completion of the response requirement, the screen changed colors displaying a printed instruction indicating that during the next three minutes the participant could take two puffs from the selected cigarette adhering to a controlled puffing protocol. Participants lit the cigarette without inhaling, inserted the cigarette into the cigarette holder filter, and then proceeded to begin puffing until a 60 mL volume of smoke had been inhaled which was displayed visually on the computer screen by a counter that incremented as puff volume increased; a second counter immediately next to the running counter showed the goal volume of 60 mL. Participants were instructed to hold the inhaled puff in their lungs for 5 s that was also displayed on a running counter followed by a 25 s inter-puff interval, also displayed as a running counter on the computer screen, after which participants were to initiate a second puff following the same regimen. Once two puffs were taken from an earned cigarette, participants extinguished the cigarette and deposited the butt in a designated container for that cigarette code. They used a new cigarette for each subsequent two puffs earned. This controlled-puffing procedure is used so that differences in nicotine exposure that should be associated with smoking the varying dose cigarettes is not altered by between-or within-participant changes in smoking topography or confounding of dose and cigarette length at the time of smoking the different dose cigarettes. [13] [14] [15] 17 Upon completion of the session, participants completed the MNWS 6 and the QSU-brief . Participants could request to smoke by directing the cursor to the desired square and associated letter code and clicking the mouse the required number of times. After completion of the response requirement, the timer at the top of the left screen displayed a running counter showing the 3-min available for smoking. Participants took puffs off the cigarette through the plastic holder shown in center of figure, which recorded puff volume and duration. The upper row of counters on the right-most screen provided visual feedback on puff volume with the goal being 60 mL. The lower row of counters provided feedback on the goal of retaining the smoke in the lungs for 5 s followed by a 25 s inter-puff interval after which the participant could take a second puff following the same regimen.
Phase 3 (Sessions 12-14)
The experimental arrangement for these three sessions was the same as in Phase 2 except that the focus was on examining preference for the lowest dose cigarette (0.4 mg/g) available at a fixed relatively low response requirement (same 10 mouse clicks as in Phase 2) vs. the highest dose (15.8 mg/g) that was available on a progressive ratio schedule that began at the same 10-response requirement but incremented upwards each time it was chosen (10, 160, 320, 640, 1280, 2400, 3600, 4800, 6000, 7200, and 8400 clicks where it remained until session end). 14 Choices to smoke resulted in the same opportunity to take 2 controlled puffs from the chosen cigarette as in Phase 2.
significantly greater than for the 0.4 mg/g dose (F1,38=7.45, p=.01). There were no significant differences across sessions or populations in these relationships. 
